Advances in Lymphoma
How will emerging evidence on treatment options change the way you work with your patients to manage lymphoma? This Learning Zone provides expert insights and guidance to support optimal treatment strategies. Choose from a range of resources, including:
- Highlights from recent major congresses, including key insights from ASCO 2024 and EHA2024 (with Professor Wojciech Jurczak), ESMO 2024 (with Professor Andrés Ferreri) and ASH 2024 (with Dr Francine Foss)
- Guidance on the latest indications for drugs targeting peripheral T-cell lymphoma (PTCL) subtypes, plus the latest clinical data to help you select the optimal classic Hodgkin lymphoma (cHL) treatments
“The era of chemo, or chemoimmunotherapy, is ending”
Professor Wojciech Jurczak, Consultant and Professor of Haematology at Maria Sklodowska-Curie National Research Institute of Oncology, on the evolving landscape of lymphoma treatment and achieving results in different ways. Stay tuned for further post-congress insights from Professor Jurczak, coming to this page soon. View transcript.
Current state of care and promising new treatments
Read our concise overview of current lymphoma care and treatment strategies, including updated indications for common PTCL subtypes, advances in the management of relapsed diffuse large B-cell lymphoma (DLBCL), and additional therapies for B-cell non-Hodgkin lymphoma (B-NHL).
of interest
are looking at
saved
next event